October 20, 2006 print issue of Journal of Clinical Oncology has published the results of Velcade or bortezomib in the 155 patient “PINNACLE” Study. Velcade is manufactured by Millennium Pharmaceuticals, in Relapsed Mantle Cell Lymphoma (MCL), which is an aggressive form of non-Hodgkin’s lymphoma (NHL). Velcade is currently under priority review with U.S. Food and Drug Administration (FDA). Velcade is approved in the United States for the treatment of multiple myeloma (MM) patients who have received at least one prior therapy. (More …)